These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25909366)

  • 1. Certolizumab pegol - A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease.
    Hurabielle C; Schneider P; Baudry C; Bagot M; Allez M; Viguier M
    J Dermatolog Treat; 2016; 27(1):67-9. PubMed ID: 25909366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn's disease: A case report.
    Pender TM; Ayandibu G; Van Voorhees AS
    Dermatol Ther; 2020 Nov; 33(6):e14352. PubMed ID: 32981217
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.
    Ferkolj I; Hocevar A; Golouh R; Dolenc Voljc M
    Acta Dermatovenerol Alp Pannonica Adriat; 2006 Dec; 15(4):173-7. PubMed ID: 17982610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
    Sapienza MS; Cohen S; Dimarino AJ
    Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of infliximab in pyoderma gangrenosum.
    Hewitt D; Tait C
    Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient.
    Wang N; Yu C; Wang W; Yang Q
    J Dermatolog Treat; 2023 Dec; 34(1):2276044. PubMed ID: 37905433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
    Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
    Lee SD; Rubin DT; Sandborn WJ; Randall C; Younes Z; Schreiber S; Schwartz DA; Burakoff R; Binion D; Dassopoulos T; Arsenescu R; Gutierrez A; Scherl E; Kayhan C; Hasan I; Kosutic G; Spearman M; Sen D; Coarse J; Hanauer S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1870-80. PubMed ID: 27400222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab.
    Boktor M; Motlis A; Aravantagi A; Sheth A; Jordan P; Morris J; Manas K; Hussain N; Cvek U; Trutschl M; Becker F; Alexander JS
    Inflamm Bowel Dis; 2016 Jun; 22(6):1353-61. PubMed ID: 27104819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
    Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
    J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
    Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
    Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.